Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2005
05/12/2005US20050101630 4-Anilino-, phenoxy-, or phenylthio-substituted; inhibitors of specific kinase enzymes, such as MEK enzymes
05/12/2005US20050101629 Compositions of a chromene cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system
05/12/2005US20050101627 Preparation of 1H-imidazo [4,5-C] quinolin-4 amines via novel 1h-imidazo [4,5-C] quinolin-4-cyano and 1h-imidazo [4,5-C] quinolin-4-carboxamide intermediates
05/12/2005US20050101626 Imidazo-fused oxazolo[4,5-beta]pyridine and imidazo-fused thiazolo[4,5-beta]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
05/12/2005US20050101625 Aerosol formulation for inhalation comprising an anticholinergic
05/12/2005US20050101623 Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors
05/12/2005US20050101622 Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists
05/12/2005US20050101621 Method for rapid detoxification of addiction
05/12/2005US20050101620 Selective synthesis of CF3-substituted pyrimidines
05/12/2005US20050101618 Selective erbB2 inhibitor/anti-erbB antibody combinations in the treatment of cancer
05/12/2005US20050101615 Pyridopyrimidine or naphthyridine derivative
05/12/2005US20050101614 Heterocyclic GABAA subtype selective receptor modulators
05/12/2005US20050101612 Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases
05/12/2005US20050101611 Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
05/12/2005US20050101610 Antiischemic agents; brain disorders; cardiovascular disorders; for the alleviation or treatment of symptoms due to neurodegenerative diseases and symptoms derived from diabetes, arteriosclerosis and inflammatory diseases ; for example, N-tert-butoxycarbonyl-4-[4-(4-fluorophenoxy)phenyl]-4-piperidinol
05/12/2005US20050101609 Quinazoline derivatives as kinase inhibitors
05/12/2005US20050101608 Iloprost in combination therapies for the treatment of pulmonary arterial hypertension
05/12/2005US20050101607 Pharmaceutical composition containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha reductase inhibitor
05/12/2005US20050101606 Sustained-release preparation containing 5-acetyl-4,6-dimethyl-2[2-[4-(2-methoxyphenyl) piperazinyl]ethylamino]pyrimidine trihydrochloride as active ingredient
05/12/2005US20050101605 with a hydrophilic nonionic polyol surfactant; for gastrointestinal administration; storage stable with little methyl folic acid formed; glycerin, polyethylene glycol, sorbitol, propylene glycol, pentaerythritol, sodium saccarin
05/12/2005US20050101603 Compound and method for the treatment of pain
05/12/2005US20050101602 For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease
05/12/2005US20050101601 Substituted tricyclic heterocycles and their uses
05/12/2005US20050101599 Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
05/12/2005US20050101598 Crystal structure antibiotic; heating, dissolving, crystallization
05/12/2005US20050101597 Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage
05/12/2005US20050101596 Such as N,N-dimethyl-3-(phenylsulfonyl)-6,7,8,9-tetrahydro-3H-benzo[e]indol-8-amine; for treatment of central nervous system disorders related to or affected by serotonin receptor antagonists such as neurodegenerative disorders, attention deficit disorder, obsessive compulsive disorder, and drug abuse
05/12/2005US20050101595 N-containing cycloalkyl-substituted amino-thiazole derivatives and pharmaceutical compositions for inhibiting cell proliferation and methods for their use
05/12/2005US20050101594 Compositions useful as inhibitors of protein kinases
05/12/2005US20050101593 Phosphoric acid salt of an integrin receptor antagonist
05/12/2005US20050101592 3-(4-chlorophenyl)-2-(2-chlorophenyl)-7-(2,2,2-trifluoroethyl)-6,7-dihydro-2H,5H-4-oxa-1,2,7-triaza-azulen-8-one; for treatment of disorders linked to mediation of cannabinoid receptors
05/12/2005US20050101590 Cannabinoid receptor agonists
05/12/2005US20050101588 7-Amino alkylidenyl-heterocyclic quinolones and naphthyridones
05/12/2005US20050101587 Such as 1-(1-{2-Hydroxy-3-[5-methanesulfonyl-3-(4-trifluoromethyl-phenyl)-4,5,6,7-tetrahydro-pyrazolo[4,3-c]pyridin-1-yl]-propyl}-piperidin-4-yl)-1,3-dihydro-benzoimidazol-2-one; cathepsin inhibitors
05/12/2005US20050101585 Cannabis-1 (CB1) receptor antagonists; for treatment/inhibiton of drug induced obesity in juveniles/adolescents
05/12/2005US20050101584 Selective estrogen receptor-beta ligands
05/12/2005US20050101582 Compositions and methods for treating a posterior segment of an eye
05/12/2005US20050101581 Fluoro-androstane derivatives for treatment of cystic fibrosis, sickle cell disease, autism, neutropenia or thrombocytpoenia
05/12/2005US20050101580 Cream base emulsion containing tretinoin, hydroquinone, and fluocinolone acetonide for treatment of hyperpigmented skin conditions such as melasma
05/12/2005US20050101579 Endometriosis treatment protocol
05/12/2005US20050101578 2-Alkylidene-19-nor-vitamin D derivatives for the treatment of hypocalcemic tetany or hypoparathyroidism
05/12/2005US20050101577 2-alkylidene-19-nor-vitamin D derivatives for the treatment of rickets or vitamin D deficiency
05/12/2005US20050101576 Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
05/12/2005US20050101573 Meiosis regulating compounds
05/12/2005US20050101572 Improved lipophilicity, toxicity, bioavailability, and pharmacokinetics; for treatment of cardiovascular and neurological disorders
05/12/2005US20050101571 Methods of treating cancer using a combination of drugs
05/12/2005US20050101569 Methods and compositions for selectin inhibition
05/12/2005US20050101568 Methods and compositions for selectin inhibition
05/12/2005US20050101567 Using a sulfonamide containing compound
05/12/2005US20050101565 Using mixture containing pantethine
05/12/2005US20050101564 Transplanting stem cells; stimulating hematopoietic cells
05/12/2005US20050101563 Using cyclooxygenase inhbitor and fatty acid; analgesics; antiinflammatory agents; antiarthritic agents; vision defects; urogenital disorders; gastrointestinal disorders
05/12/2005US20050101562 Lipase inhibiting composition
05/12/2005US20050101561 HDL-boosting combination therapy complexes
05/12/2005US20050101560 Method of treating an individual with methyl 1-[N6-(3-iodobenzyl)-adenin-9-yl] beta-D-ibofuronamide
05/12/2005US20050101557 Immunostimulatory nucleic acid molecules
05/12/2005US20050101556 Genetic engineering; Alzheimer's disease; anticancer agents
05/12/2005US20050101554 Methods for treating and preventing infectious disease
05/12/2005US20050101551 Prevent tissue or organ damage; antiischemic agents
05/12/2005US20050101550 Nucleoside compounds for treating viral infections
05/12/2005US20050101549 Prevention and treatment of endotoxemia and related complications associated with surgery
05/12/2005US20050101548 Bactericides
05/12/2005US20050101547 Stabilized as hydrates; controlling water concentration
05/12/2005US20050101546 Increased solubility flavanolignan preparations
05/12/2005US20050101545 Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
05/12/2005US20050101544 Such as montelukast, zafirlukast or pranlukast; low amounts of active agents, less prone to detrimental side effects
05/12/2005US20050101543 Treatments for neurogenetic disorders, impulse control disorders, and wound healing
05/12/2005US20050101542 Combination therapy for controlling appetites
05/12/2005US20050101536 Modulation of angiogenesis
05/12/2005US20050101535 Administering hormone inhibitor as therapy for steroid induced obesity
05/12/2005US20050101534 Side effect reduction of antibiotics; using 2- mercaptan pyrimidine compound
05/12/2005US20050101530 Cellular virus receptors and methods of use
05/12/2005US20050101528 Substituted (e)-styryl benzylsulfones for treating proliferative disorders
05/12/2005US20050101525 Method of complexing a nucleic acid with a lipid-conjugated polyamide
05/12/2005US20050101523 Antidiabetic agents; therapy for insulin resistance
05/12/2005US20050101522 Antihyperplastic agents; antitumor agents; side effect reduction
05/12/2005US20050101521 Bind as ligands to human peroxisome proliferator activated receptor to activate receptor and thereby exhibit potent effects of decreasing neutral fat, cholesterol, and blood sugar; for example, 2-[[4-ethoxy-3-[[[4-(2-pyridyloxy)phenyl]carbonylamino]methyl]phenyl]methyl]butyric acid; diabetes treatment
05/12/2005US20050101519 grinding roots, leaves or stem-bark of Physalis ssp; extracting material with solvents selected from water and alcohols such as methanol, ethanol; for treatment of autoimmune diseases, Chagas Disease or Leishmaniasis
05/12/2005US20050101518 Methods of treating conditions associated with an EDG-2 receptor
05/12/2005US20050101517 An oily solution of testosterone decanoate suitable for injections; male contracepti ves
05/12/2005US20050101004 Screening for a compound to inhibit the urge for urinary incontinence by detecting activation of KCNQ protein in the host cell; measuring the membrane potential of the host cell and selecting the compound whose presence causes hyperpolarization in themembrane potential of the host cell
05/12/2005US20050100918 Mammalian receptor proteins; related reagents and methods
05/12/2005US20050100917 Mammalian receptor proteins; related reagents and methods
05/12/2005US20050100907 Method and medicament for inhibiting the expression of a given gene
05/12/2005US20050100906 especially that encodes an immunoglobulin constant region such as the Fc portion of human IgG1.
05/12/2005US20050100902 5-cyano-1h-indole derivatives as antagonist of the inerleukine-8 receptors
05/12/2005US20050100891 Identifying modulators which control endothelial cell and viral gene expression; diagnosis and treatment of cell proliferative disorders; viricides; anticancer agents
05/12/2005US20050100889 Oligonucleotides and methods for detecting hepatitis C viral nucleic acids
05/12/2005US20050100886 Nucleotide sequences coding dengu virus non-structural and west nile structural protein for use as tool in generating attenuated west nile viral vaccine
05/12/2005US20050100885 Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)
05/12/2005US20050100882 Viral polypeptide fusion comprising guanylyltransferase, methyltransferase and polymerase activities for use as tool in identifying modulator of viral propagation; viricides
05/12/2005US20050100637 Carbohydrate and electrolyte replacement composition
05/12/2005US20050100621 comprising urea as an active ingredient, a vegetable oil or vegetable oil derivative, water, and conventional excipients
05/12/2005US20050100618 Manual clitoral sensitizing mixture having a cooling agent chosen from oils of peppermint, cornmint, eucalyptus, camphor, citronella and cinnamon
05/12/2005US20050100617 Method for improving age-related physiological deficits and increasing longevity
05/12/2005US20050100615 controling metabolic acidosis due to burn injury, hemorrhagic shock, multiple organ failure, systemic inflammatory response syndrome (SIRS); administering sodium bicarbonate
05/12/2005US20050100614 Chromium bound to niacin and three compounds from the group consisting of (-) hydroxycitric acid, zinc (particularly zinc methionine), trans-reseveratrol, gymnernic acid, selenium, an anthocyanidin, allicin, and fenugreek.
05/12/2005US20050100612 Virucidal activities of cetylpyridinium chloride
05/12/2005US20050100611 Administering a therapeutically effective amount of arsenic compounds, optionally along with other non-arsenic therapeutic agents, to a mammal for treating solid tumors
05/12/2005US20050100608 solid dosage; alleviate many of the undesirable consequences of undergoing testosterone therapy, such as the pain of injections and problems with patient noncompliance
1 ... 4693 4694 4695 4696 4697 4698 4699 4700 4701 4702 4703 4704 4705 4706 4707 4708 4709 4710 4711 4712 4713 ... 7860